SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is drawing attention after reporting record Q3 revenue above guidance and its first profitable quarter on an adjusted EBITDA basis, with Quake AI driving much of the growth. Bullish traders point to AI demand and heavy short interest as potential squeeze fuel, while skeptics focus on softer Q4 guidance, possible data-center delays and the financing required for expansion.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations and its 2026 revenue outlook fell short of consensus, prompting concern about weak commercial traction and the companys valuation. Traders are divided between skeptics focused on losses and delayed commercialization and bulls pointing to quantum-hardware progress, government support, and possible rebound momentum.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,959,453.18587388 with 16,959,453.64420722 in circulation. The last known price of Zcash is 1,033.61575403 USD and is down -11.66 over the last 24 hours. It is currently trading on 670 active market(s) with $1,322,935,861.71 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile selloff after a major rally, with traders citing lost support and broader crypto-market weakness and liquidation pressure. The community is split between calling it a deeper unwind and treating the drop as a buying opportunity, with some bulls still pointing to Zcashs privacy features and network upgrade.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs Nov. 22 decision on Capricors deramiocel application for Duchenne muscular dystrophy; the companys earnings call reaffirmed confidence in the therapy and said the application is in final review, while launch preparations are underway. Many traders read those updates and the upper-limb trial results as encouraging, but others stress the prior FDA concerns and the risk of rejection in this binary event.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have filed an FDA application for psilocybin in major depression has stirred fears that Compass Pathways could lose its first-mover advantage, amid a sharp selloff. Traders dispute how much of a threat Usona poses given its different target indication and limited commercial infrastructure, while focusing on Compasss expected completion of the COMP360 application and its planned launch in 2027.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

A Baird downgrade citing weaker visibility on future AI data-center spending and supply constraints is adding to pressure, while traders also debate allegations involving Jensen Huang and possible leadership or national-security fallout. Bulls argue AI demand remains strong and point to the rebound and CoreWeaves results, while skeptics see unresolved controversy and headline risk.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras Q3 update has focused attention on KOMZIFTIs commercial ramp, with traders highlighting rising prescriptions and new patient starts and many reacting positively to the earnings call. The debate centers on whether that momentum can hold amid competition from Johnson & Johnsons menin inhibitor and questions about how comparable the companies clinical data are.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on the expected Phase 3 APPROACH readout for Heluss HLP003 depression treatment, with bulls highlighting its add-on trial design and potential for shorter clinic sessions while stressing that the data are a major binary catalyst. Skeptics point to the risk of weaker results, possible future dilution, and competition amid reports that Usona may have filed an NDA for psilocybin.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook dominate discussion, with traders highlighting year-over-year growth, improved profitability and margins, and recurring licensing revenue from Samsung and Micron. Many are bullish on a possible SK Hynix licensing deal hinted at by the CEO, though it remains unconfirmed; others focus on the reported results falling short of expectations and lower sequential product sales.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: strong revenue growth, improving gross margins and raised guidance were offset by an earnings-per-share miss and continued losses. Traders are debating whether the selloff overreacted to the bottom-line miss or reflects concerns about profitability and cash use.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
